A Phase 1 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer

Trial Profile

A Phase 1 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs SRA 737 (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Sierra Oncology
  • Most Recent Events

    • 02 Apr 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Sep 2019.
    • 27 Feb 2018 According to a Sierra Oncology media release, 20 patients had been enrolled into Phase 2 portion of the study.
    • 27 Feb 2018 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top